Acute Lymphoblastic Leukemia News and Research

RSS
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.
Research reveals a possible strategy to prevent B-cell acute lymphoblastic leukemia

Research reveals a possible strategy to prevent B-cell acute lymphoblastic leukemia

New personalized test to detect leukemia relapse sooner and avoid false negative results

New personalized test to detect leukemia relapse sooner and avoid false negative results

Study identifies a genetic mutation linked to high risk of lethal childhood leukemia

Study identifies a genetic mutation linked to high risk of lethal childhood leukemia

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Overall survival rate has nearly doubled for Ph+ ALL patients after hematopoietic stem cell transplant

Overall survival rate has nearly doubled for Ph+ ALL patients after hematopoietic stem cell transplant

Amino acid valine plays a key role in the growth of T cell acute lymphoblastic leukemia

Amino acid valine plays a key role in the growth of T cell acute lymphoblastic leukemia

Scientists develop new immunotherapy for cancer based on transplant rejection mechanism

Scientists develop new immunotherapy for cancer based on transplant rejection mechanism

Study reveals molecular players involved in the onset of leukemia

Study reveals molecular players involved in the onset of leukemia

Researchers uncover a key role for SIRT1 enzyme in T-cell acute lymphoblastic leukemia

Researchers uncover a key role for SIRT1 enzyme in T-cell acute lymphoblastic leukemia

Drug combination without chemotherapy can be effective in treating older patients with Ph+ ALL

Drug combination without chemotherapy can be effective in treating older patients with Ph+ ALL

New genetic technology for gene expression analysis of cancer cells

New genetic technology for gene expression analysis of cancer cells

DNA sequencing of residual disease accurately identifies leukemia patients who would relapse

DNA sequencing of residual disease accurately identifies leukemia patients who would relapse

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia

New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia

Hollings Cancer Center researcher awarded NCI grant to pursue early investigator studies in leukemia

Hollings Cancer Center researcher awarded NCI grant to pursue early investigator studies in leukemia

“Batman Sam” fights cancer with care from Johns Hopkins Children’s Center

“Batman Sam” fights cancer with care from Johns Hopkins Children’s Center

An existing drug may function as targeted therapy for ALL in children

An existing drug may function as targeted therapy for ALL in children

Study illuminates genetic understanding of aggressive childhood leukemias

Study illuminates genetic understanding of aggressive childhood leukemias

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

International collaboration aims to develop better therapy for childhood acute lymphoblastic leukemia

International collaboration aims to develop better therapy for childhood acute lymphoblastic leukemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.